On June 30, 2025, Portal Biotech, a pioneering biotechnology company based in London, announced a $35 million Series A financing round—one of the largest investments in a life sciences tools company in Europe. The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with participation from existing investors Science Creates Venture Capital, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank, and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Portal Biotech on IP diligence matters related to the transaction.

Portal Biotech is developing the world’s first full-length single-molecule protein sequencer, combining a proprietary nanopore-based platform with advanced AI capabilities. The company’s breakthrough technology enables rapid and cost-effective protein characterization, with the potential to transform drug discovery, diagnostics, and global biosecurity by providing direct access to intact protein structure and modifications at the single-molecule level.

The funding will support Portal Biotech’s commercialization efforts, expand its R&D and engineering teams, and advance collaborations with pharmaceutical and biotech innovators.

The Wilson Sonsini team that advised Portal Biotech on the IP diligence matters related to the transaction included: Jing Wang, Nick Upright, and Ali Alemozafar.

For more information, please read the company’s press release or media coverage on Reuters.